Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002, for Corniche Group Incorporated (Note: The input metadata references "Lisata Therapeutics," but the filing text explicitly identifies the registrant as Corniche Group Incorporated). The Company operates an Internet-based extended warranty and service contract business (warrantysuperstore.com) but is currently pivoting toward a strategic transaction with StrandTek International, Inc., a high-tech manufacturer.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Revenue | $24,552 | $11,457 |
| Gross Profit | $5,182 | $4,042 |
| Operating Loss | $(366,253) | $(418,134) |
| Net Loss | $(341,763) | $(652,777) |
| Cash and Equivalents (End of Period) | $42,020 | $45,569 |
| Total Debt (Current + Long-term) | $47,807 | N/A |
| Notes Receivable (StrandTek Loans) | $1,250,000 | $0 |
Liquidity: The Company ended the period with $42,020 in cash. Operating activities consumed $256,136 in cash, while investing activities provided $252,240, primarily from the sale of marketable securities ($1.5M) offset by loans to StrandTek ($1.25M).
Material Changes vs. Prior Period
- Revenue Growth: Earned revenues increased to $24,552 from $11,457, driven by the recognition of deferred revenues from prior contract sales.
- Expense Reduction: General and administrative expenses decreased 12% to $371,435 (from $422,176) due to significant cuts in advertising ($67k), payroll ($50k), and technology costs, partially offset by increased professional fees related to the StrandTek transaction.
- Net Loss Improvement: Net loss decreased by approximately 15% to $341,763 compared to $652,777 in the prior year. The prior year figure included a $431,857 loss on the disposal of discontinued operations (Stamford Insurance), which did not recur in 2002.
- Asset Reallocation: Marketable securities dropped to zero as they were sold to fund operations and the proposed transaction. Conversely, Notes Receivable increased by $1.25 million due to loans advanced to StrandTek.
Guidance, Outlook, and Risks
- StrandTek Transaction: The Company is pursuing a transaction where StrandTek becomes a majority-owned subsidiary. Closing is contingent on financing via a private placement and other conditions. A closing date was anticipated for May 8, 2002, but no assurance of consummation is given.
- Current Business Strategy: Management has ceased promoting the warranty business (no new advertising) and is considering contracting, selling, or terminating this segment if the StrandTek deal closes.
- Financing Needs: The Company is conducting a private placement to sell up to 31.25 million shares at $0.40 per share to satisfy transaction conditions. Proceeds are critical for operations pending the transaction.
- Preferred Stock Redemption: The Company has called for the redemption of Series A Preferred Stock at $1.05 per share plus accrued dividends, contingent on the closing of the StrandTek transaction.
- Liquidity Risk: With only $42,020 in cash, the Company relies on the repayment of the $1.25M StrandTek loans (due 45 days after termination of the agreement) or the completion of the private placement to fund operations.
Investor Verification Checklist
- Verify the status of the StrandTek Transaction and whether the May 2002 closing date was met or extended.
- Confirm the progress of the private placement offering and whether sufficient capital has been raised to fund operations and the transaction.
- Assess the collectability of the $1.25 million loan to StrandTek, which is unsecured and contingent on the transaction's termination.
- Review the Series A Preferred Stock redemption notice and the Company's ability to fund the redemption if the transaction closes.
- Monitor the cash burn rate given the minimal cash balance ($42k) and the cessation of revenue-generating marketing activities.